Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~Subjects enrolled in V59P13:~* healthy subjects who have completed the V59P13 study.~Naïve subjects:~* healthy subjects aged-matched with subjects who had completed the V59P13 trial.(currently 16-23 years old).~Exclusion Criteria:~Subjects who had completed the V59P13 study:~* who received any meningococcal vaccine after the V59P13 trial;~* who have had previous confirmed or suspected disease caused by N. meningitidis;~* who have had household contact with and/or intimate exposure to an individual with culture-proven N. meningitidis (serogroups A, C, W135, or Y);~* subjects with any serious, acute or chronic progressive disease.~Naïve subjects:~* who previously received any meningococcal vaccine;~* who have had previous confirmed or suspected disease caused by N. meningitidis;~* who have had household contact with and/or intimate exposure to an individual with culture-proven N. meningitidis (serogroups A, C, W135, or Y);~* subjects with any serious, acute or chronic progressive disease.

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- MenACWY-CRM (Type: EXPERIMENTAL): Subjects received one primary dose of MenACWY-CRM conjugate vaccine in the parent study and were followed for persistence in the present study.
- Licensed comparator (Type: ACTIVE_COMPARATOR): Subjects received one primary dose of a quadrivalent meningococcal conjugate vaccine with diphtheria toxoid as the protein carrier in the parent study and were followed for persistence in the present study at 5 years postvaccination.
- Naive (Type: OTHER): Subjects who were age-matched to the other study groups and had not received any previous meningococcal vaccinations.
- MenACWY-CRM/MenACWY-CRM (Type: EXPERIMENTAL): Subjects received one primary dose of the MenACWY-CRM conjugate vaccine in the parent study and one booster dose of MenACWY-CRM conjugate vaccine at 3 years after primary vaccination.
- Licensed comparator/MenACWY-CRM (Type: EXPERIMENTAL): Subjects received one primary dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine in the parent study and one booster dose of MenACWY-CRM conjugate vaccine at 3 years after primary vaccination.

Based on this trial design, predict the completion outcome and termination type (if applicable).